Viewing Study NCT01077856


Ignite Creation Date: 2025-12-24 @ 11:18 PM
Ignite Modification Date: 2025-12-25 @ 8:58 PM
Study NCT ID: NCT01077856
Status: COMPLETED
Last Update Posted: 2022-09-13
First Post: 2010-02-26
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: GARDASIL™ Vaccine Impact in Population Study (V501-033)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Overview

Official Title: GARDASIL™ Vaccine Impact in Population Study
Status: COMPLETED
Status Verified Date: 2022-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: VIP
Brief Summary: This study will assess the impact of GARDASIL™ human papillomavirus (HPV) vaccine in the general female population by utilizing nationwide registry databases in the participating Nordic countries.
Detailed Description: Time perspective: The study will be conducted using data collected both retrospectively/concurrently from registries and prospectively by questionnaire survey.

Baseline survey data were collected during a prior study from 2004-2005.

Safety Monitoring: An expert panel on teratology consisting of one teratologist from each of the participating countries will review all available medical records related to any congenital anomalies to search for any emerging patterns that may be indicative of an association between GARDASIL™ exposure in the mother and the subsequent congenital anomalies in the babies.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2010_018 OTHER Merck Registration Number View
EP08014.033 OTHER Merck Study Number View